Peter Gasser


Born in 1960, married, three children. He works as a medical doctor in his private clinic in Solothurn. He has trained in psychodynamic therapy approaches, with a particular focus on bioenergetic analysis and therapy, as well as in psycholytic psychotherapy (therapy using consciousness-altering substances). Member of the Swiss doctor’s association for psycholytic therapy (Schweiz. Ärztegesellschaft für Psycholytische Therapie; SÄPT), of which he has been president since 1996. He was the head of the first psychotherapeutic LSD-study after 35 years (from 2008 until 2011).

Presentation: “Exploration of consciousness-altering substances for psychotherapeutic purposes”

A rich talk on the use of LSD in a psychotherapeutic context, mapping out the significance of the immediate intrasubjective experience of the individual, that is: their sensual, emotional and cognitive experience. Gasser will also report on the history, implementation and results of the double-blind, placebo-controlled, pilot study he conducted on the effects of LSD for people with anxiety who were facing advanced life-threatening illness (“LSD – unterstützte Psychotherapie bei Personen mit Angstsymptomatik in Verbindung mit fortgeschrittenen lebensbedrohenden Erkrankungen. Eine doppelblinde, plazebokontrollierte Phase-II Dosis-Wirkungs-Pilotstudie”).


Presse und Medien

SWR Odysse vom 27.1.2011

Drogen Comeback in der Medizin – Hanf (Cannabis, Marihuana) und LSD – SWR – Odysso

[videojs width=”500″ height=”400″]

Published on Aug 25, 2013

LSD-Assisted Psychotherapy in the Treatment of Anxiety Secondary to Life Threatening Illness

Abstract: Over time, it has become clear that LSD does not fit in the usual paradigm of psychiatric medicines but rather is a kind of catalyst of psychological processes. This altering of mind facilitates personal regressive experiences with emotional and cognitive insights in biographic material as well as deep encounters with the personal self or transpersonal openings into mystical or spiritual experiences. Further factors that are important are the creating of a trusting relationship with the therapist(s) and the ego-strengthening experience of overcoming anxiety and fear of loss of control when facing the unknown. In 2007, after a 35-year breakdown of research and therapy using mind-manifesting drugs, Dr Gasser obtained approval for a MAPS-sponsored pilot study of LSD-assisted psychotherapy in persons suffering from anxiety associated with advanced-stage life-threatening diseases. This presentation, which is taking place exactly on the 70th anniversary of Albert Hofmann’s discovery, will report on the approval, conduct, and results of this historic project.

[videojs width=”500″ height=”400″]


Interview mit Peter Gasser vom Donnerstag, 24. Mai 2012:

Über Jahrzehnte war die Forschung mit halluzinogenen Drogen ein Tabu. Inzwischen gibt es weltweit einige wenige Forscher, die erneut die Spur der Halluzinogene aufgenommen haben und neue Erkenntnisse gewonnen haben. Gert Scobel diskutiert mit seinen Gästen über die Chancen und Risiken dieses Forschungszweigs…
siehe auch: – Mediathek Interview mit Franz Vollenweider…
Highlung durch Drogen – Gesunde Wissenschaft gegen kranke Politik – DOKU Scobel…

[videojs width=”500″ height=”400″]


Tags: , , ,